AdAlta (ASX:1AD) - CEO & Managing Director, Dr Tim Oldham
CEO & Managing Director, Dr Tim Oldham
Source: Tim Oldham/LinkedIn
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • AdAlta (1AD) receives a European patent from the European Patent Office for its lead product AD-124
  • The patent is titled “CXCR4 binding molecules” and has an expiry date of January 8, 2036
  • It protects the i-body sequence used in AD-214, sequences similar to this and pharmaceutical compositions and derivatives containing the i-body sequences
  • AdAlta is now in the process of validating this patent in 18 countries across Europe which is expected to be completed by August 2022
  • On market close, 1AD are up four per cent to 5.2 cents per share

Biotechnology company AdAlta (1AD) has been granted a European patent from the European Patent Office for its lead product AD-214.

The patent is titled “CXCR4 binding molecules” and has an expiry date of January 8, 2036.

It protects the i-body sequence used in AD-214, sequences similar to this and pharmaceutical compositions and derivatives containing the i-body sequences.

The patent also protects the use of the sequences in therapeutic and diagnostic applications.

AdAlta is now in the process of validating this patent in 18 countries across Europe which is expected to be completed by August 2022. This will enable the patent to be enforced in each country.

AD-214 now has two patents in Australia and the US, and one in China, India, Japan and Singapore.

“Grant of this European patent means AD-214 now has patent protection until 2036 in the
eight largest pharmaceutical markets in the world: US, Japan, China, Germany, France,
Italy, Spain and UK,” CEO and Managing Director Dr Tim Oldham said.

On market close, 1AD were up four per cent to 5.2 cents per share.

1AD by the numbers
More From The Market Herald
Cavalier Resources (ASX:CVR) - Executive Technical Director, Daniel Tuffin

" Cavalier Resources (ASX:CVR) begins PFS at Crawford

Cavalier Resources (ASX:CVR) has begun a pre-feasibility study (PFS) at the Crawford Gold Project within the…
Ten Sixty Four (ASX:X64) - Outgoing Managing Director, Paul Ryan Welker

" Ten Sixty Four (ASX:X64) terminates services agreement of former MD, Paul Ryan Welker

Ten Sixty Four (ASX:X64) has terminated the executive services agreement of former Managing Director Paul Ryan…

" M3 Mining (ASX:M3M) identifies drill targets at Edjudina

M3 Mining (ASX:M3M) has identified prospective gold-in-soil anomalies at the Edjudina gold project 150 kilometres northeast…

" Good Drinks Australia (ASX:GDA) commences the sale of Molson Coors and Magners

Good Drinks Australia (ASX:GDA) begins to sell the Miller Chill, Miller Genuine Draught, Coors, Molson Canadian…